CEA、CA125、CA15-3在吉西他滨治疗乳腺癌化疗前后的表达及意义

The expression and significance of CEA, CA125 and CA15-3 in breast cancer before and after gemcitabine chemotherapy

目的探讨血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)和糖类抗原15-3(CA15-3)在吉西他滨治疗乳腺癌化疗前后的表达及意义。方法选取接受吉西他滨药物化疗的70例女性原发性乳腺癌患者,治疗21 d后评价疗效,并用电化学发光免疫分析技术检测患者化疗前后血清中CEA、CA125、CA15-3的浓度并进行比较。结果患者血清CEA、CA125和CA15-3浓度在吉西他滨化疗后明显降低,差异均有统计学意义(P﹤0.01)。且患者血清CEA、CA125和CA15-3浓度与吉西他滨的疗效呈正相关(rs﹥0,P﹤0.05)。结论 CEA、CA125、CA15-3对临床诊断乳腺癌的发生发展过程具有重要作用。乳腺癌患者应用吉西他滨化疗可明显降低血清CEA、CA125、CA15-3水平,且3种肿瘤标志物与吉西他滨的化疗疗效具有相关性。

Objective To investigate the expression and significance of CEA, CA125 and CA15-3 in breast cancer before and after gemcitabine chemotherapy. Method 70 women with primary breast cancer underwent chemotherapy with gemcitabine for 21 days were evaluated for efficacy, the electrochemiluminescence immunoassay was used to detect the serum CEA, CA125 and CA15-3 for comparison. Result The levels of serum CEA, CA125 and CA15-3 were significantly decreased after gemcitabine chemotherapy（P〈0.01）. And the serum CEA, CA125 and CA15-3 concentrations were positively correlated with the therapeutic effect of gemcitabine（rs0, P〈0.05）. Conclusion CEA, CA125 and CA15-3 play an important role in the clinical occurrence and development of breast cancer. The application of gemcitabine in breast cancer patients can significantly reduce serum CEA, CA125, and CA15-3 levels, and the three tumor markers are associated with the efficacy of gemcitabine chemotherapy.